Literature DB >> 2540273

Construction of a physiologically active photoaffinity probe based on the structure of bradykinin: labelling of angiotensin converting enzyme but not candidate bradykinin receptors on NG108-15 cells.

J G de Vries1, E Phillips, C R Snell, P H Snell, M Webb.   

Abstract

The peptides bradykinin and kallidin are released in response to noxious stimuli and mediate various physiological effects, including a direct stimulation of nociceptive afferent neurones. The nature of the receptor molecules through which these ligands act is presently unknown. We synthesised an iodinatable photoaffinity probe, N epsilon-4-azidosalicylylkallidin, and used it in an attempt to identify candidate bradykinin receptors on the NG108-15 neuroblastoma X glioma hybrid cell line. The ligand bound in subdued light to a particulate fraction of NG108-15 tumours and could be displaced by bradykinin with an IC50 of 0.33 nM. In a physiological assay, it behaved as an agonist equipotent with bradykinin. Gel analysis of the labelled products after photolysis of the iodinated ligand in the presence of NG108-15 cells or tumour membranes revealed bradykinin-blockable labelling of a glycoprotein with an Mr of 166,000. The probe was also able to label purified commercial angiotensin converting enzyme. The band labelled in NG108-15 cells was immunoprecipitable with a polyclonal antiserum to angiotensin converting enzyme, an enzyme shown to be present in low amounts in these preparations by direct binding using the iodinatable specific ligand MK351A.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2540273     DOI: 10.1111/j.1471-4159.1989.tb09201.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  2 in total

Review 1.  Mass receptor screening for new drugs.

Authors:  R M Burch; D J Kyle
Journal:  Pharm Res       Date:  1991-02       Impact factor: 4.200

2.  Expression cloning of a rat B2 bradykinin receptor.

Authors:  A E McEachern; E R Shelton; S Bhakta; R Obernolte; C Bach; P Zuppan; J Fujisaki; R W Aldrich; K Jarnagin
Journal:  Proc Natl Acad Sci U S A       Date:  1991-09-01       Impact factor: 11.205

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.